Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.08B |
| Gross Profit (TTM) | $609.45M |
| EBITDA | $6.65M |
| Operating Margin | -0.84% |
| Return on Equity | -36.70% |
| Return on Assets | -0.70% |
| Revenue/Share (TTM) | $15.64 |
| Book Value | $1.94 |
| Price-to-Book | 9.56 |
| Price-to-Sales (TTM) | 1.09 |
| EV/Revenue | 1.469 |
| EV/EBITDA | 345.75 |
| Quarterly Earnings Growth (YoY) | -37.00% |
| Quarterly Revenue Growth (YoY) | 13.80% |
| Shares Outstanding | $69.58M |
| Float | $63.95M |
| % Insiders | 1.17% |
| % Institutions | 116.52% |
Volatility is currently expanding
Tandem Diabetes Care NASDAQ: TNDM reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distribution could weigh on revenue growth next year.
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. TNDM is well-poised to grow in the coming quarters as the rising prevalence of diabetes and increasing adoption of connected care continue to support demand for automated insulin delivery. The company's pay-as-you-go reimbursement model could lower upfront barriers for pump starts and support higher supply revenue per customer over time.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TNDM and any ticker you trade — then tracks every position and per-strategy win rate.
